North America Pancreatic Cancer Precision Medicine Market Size & Outlook
The pancreatic cancer precision medicine market in North America is expected to reach a projected revenue of US$ 1,291.6 million by 2033. A compound annual growth rate of 18.6% is expected of North America pancreatic cancer precision medicine market from 2026 to 2033.
- Pharmaceuticals
- Oncology Drugs
- Pancreatic Cancer Precision Medicine Market Outlook
- Oncology Drugs
Revenue, 2025 (US$M)
$332.5
Estimate, 2026 (US$M)
$391.9
Forecast, 2033 (US$M)
$1,291.6
CAGR, 2026 - 2033
18.6%
North America Pancreatic Cancer Precision Medicine Market, 2021-2033 (US$M)
Global Market
Related Markets
GVR research-powered AI
Ask Prism AI about the pancreatic cancer precision medicine market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
North America pancreatic cancer precision medicine market outlook highlights
- The North America pancreatic cancer precision medicine market outlook generated a revenue of USD 332.5 million in 2025.
- The market is expected to grow at a CAGR of 18.6% from 2026 to 2033.
- In terms of segment, targeted therapy was the largest revenue generating therapeutic approach in 2025.
- Chemotherapy-Precision Combinations is the most lucrative therapeutic approach segment registering the fastest growth during the forecast period.
- Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
| Market revenue in 2025 | USD 332.5 million |
| Market revenue in 2033 | USD 1,291.6 million |
| Growth rate | 18.6% (CAGR from 2026 to 2033) |
| Largest segment | Targeted Therapy |
| Fastest growing segment | Chemotherapy-Precision Combinations |
| Historical data covered | 2021 - 2024 |
| Base year for estimation | 2025 |
| Forecast period covered | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations, Other Therapeutic Approaches |
| Key market players worldwide | Astrazeneca Plc, Pfizer Inc, Novartis Ag Adr, Amgen Inc, Roche Holding Ag, Bayer Ag, Eli Lilly And Co, Merck Kgaa, Teva Pharmaceutical Industries Ltd, Pharmacyte Biotech, Inc., Genentech, Guardant Health Inc, Illumina Inc, Thermo Fisher Scientific Inc, Foundation Medicine |
Other key industry trends
- In terms of revenue, North America region accounted for 42.7% of the global pancreatic cancer precision medicine market outlook in 2025.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 785.6 million by 2033.
No credit card required*
Publish Date: Sep 02, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pancreatic Cancer Precision Medicine Market Scope
Pancreatic Cancer Precision Medicine Market segmentation & scope
Pancreatic Cancer Precision Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Novartis AG ADR | View profile | 76,057 | Lichtstrasse 35, Basel, Switzerland, 4056 | www.novartis.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37,851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | www.tevapharm.com |
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Roche Holding AG | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Illumina Inc | View profile | 9,300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | www.illumina.com |
| Guardant Health Inc | View profile | 1,779 | 3100 Hanover Street, Palo Alto, CA, United States, 94304 | www.guardanthealth.com |
| Bayer AG | View profile | 99,723 | Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 | www.bayer.com |
North America Pancreatic Cancer Precision Medicine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pancreatic Cancer Precision Medicine Market Outlook will help companies and investors design strategic landscapes.
Targeted Therapy was the largest segment with a revenue share of 66.59% in 2025.
Horizon Databook has segmented the North America pancreatic cancer precision medicine market based on targeted therapy, immunotherapy, chemotherapy-precision combinations, other therapeutic approaches covering the revenue growth of each sub-segment from 2021 to 2033.
- North America Pancreatic Cancer Precision Medicine Market Therapeutic Approach Outlook (Revenue, USD Million , 2021-2033)
- Targeted Therapy
- Immunotherapy
- Chemotherapy-Precision Combinations
- Other Therapeutic Approaches
- North America Pancreatic Cancer Precision Medicine Market Diagnostic Technology Outlook (Revenue, USD Million , 2021-2033)
- Genomic Testing
- Molecular Diagnostics
- Liquid Biopsy
- Biomarker-based Companion Diagnostics
- Others (Immunohistochemistry (IHC), Proteomics, Mass spectrometry)
Reasons to subscribe to Pancreatic Cancer Precision Medicine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pancreatic Cancer Precision Medicine Market Outlook databook
- Our clientele includes a mix of Pancreatic Cancer Precision Medicine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Pancreatic Cancer Precision Medicine Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Pancreatic Cancer Precision Medicine Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Pancreatic Cancer Precision Medicine Market, 2021-2033 (US$M)
North america pancreatic cancer precision medicine market statistics, by therapeutic approach 2021 - 2033 (US$M)
